Study Finds Mirtazapine Eases Meth Withdrawal Cravings

Methamphetamine use disorder has no FDA-approved medication for treatment, which makes every new clinical trial in this space worth watching.

A small randomized trial published in the Journal of Addiction Medicine found that mirtazapine, an antidepressant already used for other conditions, significantly reduced cravings in men going through medical detox for methamphetamine.

What the Study Found

Researchers randomly assigned 44 hospitalized men with a diagnosed methamphetamine use disorder to receive either mirtazapine (15 to 30 mg per day) or a placebo for eight weeks, alongside standard inpatient psychosocial care. Forty-two of the 44 participants completed the full eight weeks.

By week eight, participants taking mirtazapine reported significantly lower craving scores than those on placebo, a difference researchers described as large. Relapse, confirmed through weekly urine testing, occurred in about 14% of the mirtazapine group compared to about 46% of the placebo group.

That gap looks meaningful, but the statistical analysis fell just short of the threshold researchers use to call a result definitive, so it represents a promising signal rather than proof that mirtazapine prevents relapse. Side effects were mild to moderate, and no serious adverse events were reported.

Why This Matters for Medical Detox

Medical detox for methamphetamine looks different from opioid or alcohol detox because there’s no equivalent to buprenorphine or naltrexone approved specifically for stimulants.

Craving and psychological symptoms, rather than dangerous physical withdrawal, tend to drive relapse risk in early recovery from meth. A medication that measurably reduces craving during the highest-risk window could give inpatient programs another tool alongside counseling and structured psychosocial care.

It’s worth being clear about the limits of this particular trial. It involved only 44 men at a single hospital, so it doesn’t tell us how mirtazapine performs in women, in outpatient settings, or across more diverse patient populations. Larger trials would need to confirm these findings before mirtazapine becomes a standard part of methamphetamine detox protocols.

Understanding Mirtazapine

Mirtazapine is a tetracyclic antidepressant that’s been on the market for decades and is generally well tolerated. In this trial, researchers used it off-label, meaning outside its FDA-approved use, to target the craving and mood symptoms that commonly accompany methamphetamine withdrawal.

Because it’s an older, inexpensive generic medication, clinicians believe patients might have easier access for treatment programs than a newly developed drug if future research supports its use.

Finding Medical Detox

If you or someone you love is struggling with methamphetamine use, medical detox provides structure and clinical support that’s difficult to replicate at home. Search detox.com’s directory to find detox centers in your area. Call 800-996-6135(Sponsored) to learn more about your treatment options.